Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Actinium-225 RTX 2358

Next Previous
Drug Profile

Actinium-225 RTX 2358

Alternative Names: [Ac-225] RTX-2358; Actinium-225-RTX-2358; FAP-[Ac225]

Latest Information Update: 12 Dec 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ratio Therapeutics
  • Class Antineoplastics; Radioisotopes; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Soft tissue sarcoma

Most Recent Events

  • 12 Nov 2025 Phase-I/II clinical trials in Soft tissue sarcoma (Late-stage disease, Second-line therapy or greater) in USA (IV) (NCT07156565)
  • 09 Sep 2025 Ratio Therapeutics plans phase I trial in Sarcoma in October 2025 (IV) (NCT07156565)
  • 05 Sep 2025 Preclinical trials in Soft tissue sarcoma in USA (IV), before September 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top